astrazeneca hit drug failure share angloswedish drug close 8 uk trade failure iressa drug major clinical trial lung cancer drug significantly prolong survival patient disease setback group follow rejection us october anticoagulant pill exanta meanwhile another major money spinner cholesterol drug crestor face mount safety concern two three blockbuster drug meant power company forward fail get risk crestor say nick turner analyst broker jefferies astrazeneca hop pitch iressa drug rival medicine tarceva iressa prove placebo extend life trial involve 1692 patient tarceva make osi pharmaceutical genentech roche already prove successful help prolong life lung cancer patient aztrazeneca now appoint new executive director board john patterson will charge drug development company say mr patterson make substantial change clinical organisation process determine improve development regulatory performance restore confidence company value shareholder say chief executive tom mckillop 